9:00 am Chair’s Opening Remarks

9:00 am An Overview of the Successful Development of Loncastuximab tesirine, a PBD Based ADC Directed Against CD19 for the Treatment of Hematological Malignancies


• Review thepreclinical data for IND approval
• Gain an overview of manufacturing strategy
• Analyze the clinical data

Looking at Future Approvals & Current Pioneering Scientific Developments

9:20 am ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform


  • Site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
  • We report a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
  • Both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology

9:40 am Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation

  • Dario Neri Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, , ETH Zürich & Co-founder, Philogen


• Comparative biodistribution analysis of ADCs and SMDCs
• Comparative therapeutic performance of ADCs and SMDCs
• Exploring combination opportunities

10:00 am Live Discussion & Question Time

  • Dario Neri Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, , ETH Zürich & Co-founder, Philogen
  • Patrick Van Berkel Senior Vice President - Resesarch & Development, ADC Therapeutics
  • Brian Mendelsohn Director , Ajinomoto Bio-Pharma Services

10:30 am Morning Refreshments & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new
contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through
this exclusive virtual speed networking!

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations
with. Get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business

1:00 pm Lunch & Networking

Looking at & Enhancing Novel Technologies & Hearing the Patients’ Story

2:00 pm Leveraging VelocImmuneTM Technologies to Advance Development of Next-Generation Antibody Conjugates

  • Bill Olson Senior Vice President, Therapeutic Proteins, Regeneron


• Regeneron’s VeclociSuiteTM technologies enable rapid generation of large panels of novel fully human antibodies, bispecific antibodies and humanized mouse models
• Reviewing these and other key technology platforms that provide powerful tools for generating and preclinically evaluating
innovative antibody conjugates spanning diverse disease areas and therapeutic mechanisms of action
• Outlining select examples that include conventional and bispecific antibodies conjugated to cytotoxic and immune-modulating agents

2:20 pm Tumor-Targeted Delivery of a TLR7 Agonist by Site-Specific Antibody-Drug Conjugate


• TLR agonist therapies are largely restricted to intratumoral administration due to systemic toxicity

• Ambrx has developed a platform to enable tumor targeted delivery of a TLR7 agonist via homogenous,
site-specific antibody-drug conjugate (ADC)

• Review how tumor-targetedTLR7 agonist ADCs induce potent anti-tumor immune responses and outperform systemically administered TLR7 agonist

2:40 pm Live Discussion & Question Time

3:00 pm Afternoon Refreshments & Networking Scientific Poster Session

4:00 pm Sharing an Update on Trodelvy: Next Steps


  • Looking at the milestones
  • Reviewing the current data
  • Update on development plans for Trodelvy

4:20 pm Tumor-Targeted Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-oncology Therapeutics

  • Brian Safina Vice President - Chemistry, Bolt Biotherapeutics


• Introducing Bolt’s ISAC technology platform as the next evolution in immune-oncology and antibody drug conjugates
• Showcasing key features of ISAC technology and mechanism of action
• Demonstrating the promise of the ISAC platform and Bolt’s approach to develop this new class

4:40 pm A Kadcyla Patient’s Experience: Hope & Healing


• One in eight
• Fight for life
• Better than before

5:00 pm Live Discussion & Question Time

5:30 pm Chair’s Closing Remarks